AWARD
Q -- High Throughput SARS-CoV-2 Binding Antibody Immunoassay for Testing of Clinical Samples and Variant Assessment
- Notice Date
- 1/10/2022 5:29:03 AM
- Notice Type
- Award Notice
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- BARDA - ASPR / DAAPPO / BARDA DCMA WASHINGTON DC 20515 USA
- ZIP Code
- 20515
- Solicitation Number
- 75A50122R00007
- Archive Date
- 02/09/2022
- Point of Contact
- Jeffrey Schmidt, Phone: 2022050260
- E-Mail Address
-
jeffrey.schmidt2@hhs.gov
(jeffrey.schmidt2@hhs.gov)
- Award Number
- 75A50122C00013
- Award Date
- 01/04/2022
- Awardee
- Nexelis Laboratories Canada Inc PQ H7V 3S8 CAN
- Award Amount
- 14725590.10
- Description
- ""High Throughput SARS-CoV-2 Binding Antibody Immunoassay for Testing of Clinical Samples and Variant Assessment"" The USG has a need for laboratory assay capacity sites for analysis of serum samples collected from subjects enrolled in COVID-19 vaccine clinical trials to provide serologic data to support the establishment of a correlate of protection to help facilitate expanded use of approved COVID-19 vaccines and accelerated approvals of additional vaccines.� Serum samples are tested to ascertain the ability of the vaccine to induce an immune response. The SARS-CoV-2 spike protein (S), which mediates binding to host cells, is highly immunogenic with the receptor-binding domain (RBD) being the target of many neutralizing antibodies. Serological analyses of COVID-19 vaccine trial specimens must be performed using the high throughput multiplex MSD-ECL immunoassay because it allows for simultaneous measurement of multiple SARS-CoV-2 proteins in the same well. The objectives of this contract are: (1) test the clinical trial samples of COVID-19 vaccines using the validated MSD-ECL immunoassay for COVID-19 in compliance with Good Clinical Laboratory Practice (GCLP); (2) develop and validate assays for SARS-CoV-2 emerging variants by the Contractor; and (3) test serum samples from human subjects enrolled in clinical trials of COVID-19 vaccines using the variant assay in compliance with GCLP.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/e7c5a09e08564df5a8fed58bc6df5ed5/view)
- Place of Performance
- Address: Seattle, WA, USA
- Country: USA
- Country: USA
- Record
- SN06212696-F 20220112/220110230055 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |